pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
630
stories
24d
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
24d
5 biggest venture capital raises of Q3 2026
biospace
24d
CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
fiercebiotech
24d
Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
biopharma dive
24d
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
biospace
24d
Forbion gets Lilly's backing in Dutch VC's largest-ever fundraising haul
endpoints
25d
The top biopharma conferences in 2027
biopharma dive
25d
Forbion’s ‘landmark’ €2.3B fundraise to benefit 30 ‘high potential’ biotechs
fiercebiotech
25d
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
25d
Genmab details ovarian cancer data; Lilly's Jaypirca gets a label expansion
endpoints
25d
Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
biospace
25d
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
biopharma dive
25d
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
stat
26d
How AI is transforming biopharma manufacturing facilities of the future
biopharma dive
28d
Eli Lilly’s best-ever weight loss data; Sanofi, Regeneron re-up for $1B upfront; and more
endpoints
28d
Gate CEO sees expanded $870M pact with Lilly as ‘vote of confidence’ in biotech’s platform
fiercebiotech
28d
Lilly signals move into aesthetics, looking to add products for body, skin and hair
endpoints
28d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
28d
STAT+: Lilly bypasses Australian pharmacies with DTC model
stat
28d
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
28d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
29d
Mistrust in science and a juicy gene-editing lawsuit
stat
29d
3 takeaways from a European obesity scientific meeting
biopharma dive
29d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
29d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
29d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
29d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
29d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
29d
Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff
endpoints
29d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
← prev
page 4 of 21
next →
